203 related articles for article (PubMed ID: 24863880)
1. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1.
Kim BR; Dong SM; Seo SH; Lee JH; Lee JM; Lee SH; Rho SB
Cell Signal; 2014 Sep; 26(9):1765-73. PubMed ID: 24863880
[TBL] [Abstract][Full Text] [Related]
2. MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
Kim BR; Lee SH; Park MS; Seo SH; Park YM; Kwon YJ; Rho SB
Oncol Rep; 2016 Feb; 35(2):1041-8. PubMed ID: 26555156
[TBL] [Abstract][Full Text] [Related]
3. High-mobility group box 1 (HMGB1) protein regulates tumor-associated cell migration through the interaction with BTB domain.
Ko YB; Kim BR; Nam SL; Yang JB; Park SY; Rho SB
Cell Signal; 2014 Apr; 26(4):777-83. PubMed ID: 24412753
[TBL] [Abstract][Full Text] [Related]
4. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH
Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf-3 (DKK-3) obstructs VEGFR-2/Akt/mTOR signaling cascade by interacting of β2-microglobulin (β2M) in ovarian tumorigenesis.
Kim BR; Lee EJ; Seo SH; Lee SH; Rho SB
Cell Signal; 2015 Nov; 27(11):2150-9. PubMed ID: 26278164
[TBL] [Abstract][Full Text] [Related]
6. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
Hong X; Yu JJ
Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
[TBL] [Abstract][Full Text] [Related]
7. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
[TBL] [Abstract][Full Text] [Related]
8. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
Brekhman V; Lugassie J; Zaffryar-Eilot S; Sabo E; Kessler O; Smith V; Golding H; Neufeld G
FASEB J; 2011 Jan; 25(1):55-65. PubMed ID: 20802105
[TBL] [Abstract][Full Text] [Related]
9. Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer.
Wang C; Xu S; Tian Y; Ju A; Hou Q; Liu J; Fu Y; Luo Y
Neoplasia; 2019 Apr; 21(4):413-427. PubMed ID: 30925417
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma.
Lv GQ; Zou HY; Liao LD; Cao HH; Zeng FM; Wu BL; Xie JJ; Fang WK; Xu LY; Li EM
Biochem Cell Biol; 2014 Oct; 92(5):379-89. PubMed ID: 25275797
[TBL] [Abstract][Full Text] [Related]
11. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
[TBL] [Abstract][Full Text] [Related]
12. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
[TBL] [Abstract][Full Text] [Related]
13. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways.
Wu MH; Lo JF; Kuo CH; Lin JA; Lin YM; Chen LM; Tsai FJ; Tsai CH; Huang CY; Tang CH
J Cell Physiol; 2012 Aug; 227(8):3016-26. PubMed ID: 21959927
[TBL] [Abstract][Full Text] [Related]
14. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR
Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967
[TBL] [Abstract][Full Text] [Related]
16. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.
Barker HE; Bird D; Lang G; Erler JT
Mol Cancer Res; 2013 Nov; 11(11):1425-36. PubMed ID: 24008674
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Processing of Lysyl Oxidase-like 2 and Its Effect on Amine Oxidase Activity.
Okada K; Moon HJ; Finney J; Meier A; Mure M
Biochemistry; 2018 Dec; 57(51):6973-6983. PubMed ID: 30499665
[TBL] [Abstract][Full Text] [Related]
18. RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling.
Zhou YJ; Yang ML; He X; Gu HY; Ren JH; Cheng ST; Fu Z; Zhang ZZ; Chen J
J Exp Clin Cancer Res; 2024 Feb; 43(1):45. PubMed ID: 38326908
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Cx43 phosphorylation in 5'-N-ethylcarboxamide-induced migration and proliferation of mouse embryonic stem cells.
Kim MO; Lee YJ; Han HJ
J Cell Physiol; 2010 Jul; 224(1):187-94. PubMed ID: 20232318
[TBL] [Abstract][Full Text] [Related]
20. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
